|
|
||||||||
Enables APC to Promote Memory Th17 and Abate Th1 Cell Development1



* Department of Surgery, University of Michigan, Ann Arbor, MI 48109;
Department of Surgery, Union Hospital, Wuhan, China; and
Department of Dermatology and Department of Oncology, Johns Hopkins University, Baltimore, MD 21231
| Abstract |
|---|
|
|
|---|
targets naive T cells and inhibits Th17 development. However, Th1, Th17, and memory but not naive T cells are colocalized in an inflammatory environment. To demonstrate the kinetic relationship between these T cell subsets, we investigated the role of IFN-
in regulating the development and balance between Th17 and Th1 in humans. We show that IFN-
stimulates B7-H1 expression on APC subsets and abates their Th1 polarization capacity in a B7-H1-dependent manner. Interestingly, IFN-
triggers APCs to produce IL-1 and IL-23 and enables them to induce memory Th17 expansion via IL-1 and IL-23 in a B7-H1-independent manner. We propose a novel dynamic between Th1 and Th17 in the course of inflammation as follows: Th1-mediated inflammation is attenuated by IFN-
-induced B7-H1 on APCs and is evolved toward Th17-mediated chronic inflammation by IFN-
-induced, APC-derived IL-1 and IL-23. Our study challenges the dogma that IFN-
suppresses Th17 and enhances Th1 development. | Introduction |
|---|
|
|
|---|
(10, 11, 12). However, memory but not naive T cells predominantly accumulate in the inflammatory environment. Further, Th1 and Th17 cells are often colocalized in pathological environments (1, 2, 3, 4, 5, 6, 7, 8, 9). Altogether, this suggests that kinetic interaction between Th1 and Th17 cells may possibly be involved in regulating the evolution of inflammation in pathological environments.
IFN-
stimulates B7-H1 expression on human monocytes and tumor cells (13, 14, 15). B7-H1 is one of the newly defined inhibitory B7 family molecules (16, 17, 18). In this study, we examined how and why IFN-
enables APCs to promote Th17 and abate Th1 cell development in humans.
| Materials and Methods |
|---|
|
|
|---|
Normal peripheral blood CD4+, naive (CD45RO–CD25–), and memory T cells (CD45RO+CD25) and CD14+ monocytes/macrophages were enriched and sorted as we described previously (19, 20). Monocyte differentiated dendritic cells (MDDCs)3 were generated with GM-CSF and IL-4 in vitro for 5 days (21).
Treatment of APCs
APCs including MDDCs and CD14+ cells (0.5–1 x 106/ml) were incubated for 0–3 days with IFN-
(0–100 ng/ml), IL-6 (5 ng/ml), IL-10 (5 ng/ml), and M-CSF (10 ng/ml) (R&D Systems). B7-H1 expression was detected by FACS (13, 14). After incubation with cytokines, APCs were stimulated for 12 h with LPS (1 µg/ml) and then washed and used to stimulate T cell responses. In some cases, APCs were stimulated with LPS for 24 h. Quantification of gene expression in the cultured APCs was performed as we described previously (19, 20). The supernatants were collected for detection of cytokines by ELISA (all from R&D Systems, except IL-23p19 from eBioscience).
T cell culture system
The treated APCs were cultured with T cell subsets (0.5 x 106 T cells/ml) in ratios of 1:1 to 1:10 for 5 days in the presence of anti-CD3 (5 µg/ml) and anti-CD28 (2.5 µg/ml) mAbs (BD Biosciences). In some cases, T cells were labeled with CFSE (22). IL-1β (2.5 ng/ml), IL-23 (10 ng/ml), anti-IL-1 (1 µg/ml anti-IL-1R plus 1 µg/ml anti-IL-1
) (all from R&D Systems), and anti-human B7-H1 (13, 14) were used as indicated. In some cases, before culturing with T cells the APCs were exposed to IFN-
(100 ng/ml) for 72 h and/or were transfected with plasmids containing human IL-23-specific small interfering RNA (siRNA) (23). T cell phenotype and cytokine profiles were determined by FACS, ELISA, or real-time PCR (19, 20).
Statistical calculations
The Wilcoxon rank-sum test was used to determine pairwise differences and the
2 test was used to determine differences between groups. p < 0.05 was considered significant (StatSoft).
| Results |
|---|
|
|
|---|
abates the Th1 polarization capacity of APCs
Th1 cell-derived IFN-
targets T cells and NK cells to further enhance Th1 responses (24). In this study we tested the effects of IFN-
on APC-mediated T cell polarization. We incubated MDDCs or CD14+ cells with IFN-
and used these IFN-
-conditioned APCs to stimulate total T cell responses. We observed that T cell IFN-
was significantly reduced by IFN-
-conditioned MDDCs, as compared with medium-conditioned MDDCs (Fig. 1A). Similar results were obtained with IFN-
-conditioned CD14+ cells. We further sorted naive and memory T cells. We observed that IFN-
-conditioned MDDCs mediated reduced IFN-
-expressing T cells from both naive and memory T cells (not shown). This indicates that IFN-
abates the Th1 polarization capacity of APCs. IFN-
stimulates the inhibitory B7 family member B7-H1 on human monocytes and tumor cells (13, 14, 15). We showed that B7-H1 expression was dramatically increased on MDDCs and macrophages following IFN-
treatment (Fig. 1B). The effects were IFN-
dose dependent (Fig. 1C). Anti-human B7-H1 recovered T cell IFN-
expression stimulated by IFN-
-conditioned APCs (Fig. 1D). The data indicate that IFN-
stimulates B7-H1 expression on APCs and abates the Th1 polarization capacity of APCs through B7-H1.
|
programs APCs to stimulate Th17 cell developmentExogenous cytokines, including TGFβ and IL-6, induce Th17 cell development (2, 4, 5, 6, 7, 8, 9). To mimic physiologic and pathological environments in vivo, we initially examined the roles of APCs in inducing Th17 cells in the absence of exogenous cytokines. We showed that both macrophages and MDDCs were capable of inducing high levels of T cell IL-17 production, whereas in the absence of APCs the levels of Th17 cells were negligible (Fig. 2A). Interestingly, macrophages were significantly superior to MDDCs in inducing Th17 cell responses (Fig. 2A). This indicates that APCs contribute to Th17 cell polarization in humans.
|
abates the Th1 polarization capacity of APCs through B7-H1 (Fig. 1D). Because Th1 and Th17 cells are often colocalized in the inflammatory environment (1, 2, 3, 4, 5, 6, 7, 8, 9), we next investigated whether IFN-
affected the capacity of APCs to induce Th17 cells. To test this possibility, normal blood CD14+ cells were conditioned with IFN-
and tested for their capacity to induce Th17 cells. IFN-
profoundly increased the capacity of CD14+ cells to elicit IL-17+ T cells (Fig. 2B). To determine whether this is a selective feature for IFN-
, we also treated CD14+ cells with IL-6, IL-10, and M-CSF. We showed that treatment of IL-6, IL-10, and M-CSF had minimal effects on CD14+ cell-mediated Th17 cell development (Fig. 2B). IFN-
-treated macrophages or IFN-
-treated MDDCs resulted in increased secretion of T cell IL-17 (Fig. 2C). Further, we showed that IFN-
-treated APCs induced T cell IL-17 production in a dose-dependent manner (Fig. 2D). The data indicate that in contrast to the effects on Th1 polarization, IFN-
can selectively condition APCs to promote Th17 cell development. APCs stimulate memory IL-17+ T cell expansion
APCs induce Th17 cell development (Fig. 2A). We sorted naive and memory T cells and examined whether APCs stimulate memory Th17 cell expansion or Th17 cell differentiation from naive T cells. Macrophages stimulated minimal numbers of Th17 cells from naive T cells during 5 days of culture (Fig. 3A), but both MDDCs and macrophages induced Th17 cells and elicited robust production of IL-17 by memory T cells (Fig. 3, A and B). LPS stimulation moderately increased this T cell IL-17 production (Fig. 3B).
|
-conditioned APCs also stimulated memory IL-17+ T cell proliferation rather than Th17 cell differentiation from naive T cells (not shown). Taken together, these results suggest that APCs may maintain a memory Th17 cell pool in the inflammatory environment in humans. APC-induced memory Th17 cell expansion is IL-1 and IL-23 dependent
We further investigated the mechanism by which APCs induce Th17 cell expansion. We (20) and others have demonstrated that IL-1 and IL-23 are involved in the induction of Th17 cells (1, 2, 3, 4, 5, 6, 7, 8, 9). We confirmed that in the presence of APCs, T cell IL-17 production was enhanced by IL-1 and IL-23 (Fig. 4A).
|
. The expression of IL-12p35 and IL-12p40 transcripts was increased by 2- to 3-fold, and IL-23p19 expression was increased by 50-fold at 72 h (Fig. 4B). IFN-
also enhanced the expression of IL-1
and IL-1β by macrophages (Fig. 4C). Although IFN-
increased the protein levels of IL-23p19, IL-12p40, and IL-12p70, the levels of IL-23p19 were significantly higher than those of IL-12p70 (Fig. 4D).
We next examined the role of macrophage-derived IL-1 and IL-23 in the induction of Th17 cell expansion. We used neutralizing Abs blocking the IL-1 signal and siRNA sequences that specifically block human IL-23 (not shown). Separate blockade of IL-1 and IL-23 each reduced T cell IL-17 production induced by macrophages and IFN-
-conditioned macrophages. Simultaneous blockade of both cytokines abrogated the IL-17 response (Fig. 4E). Interestingly, blocking B7-H1 with anti-B7-H1 increased IFN-
+IL-17– T cells and had no significant effect on IFN-
–IL-17+ T cells and IFN-
+IL-17+ T cells (Fig. 4F). Taken together, our data indicate that APCs expand memory Th17 cells through IL-1 and IL-23 in a B7-H1-independent manner, and this effect is further amplified by IFN-
treatment.
| Discussion |
|---|
|
|
|---|
on APCs to induce Th1 and Th17 cell development in humans.
We first show that IFN-
potently stimulates B7-H1 expression on APCs. IFN-
-conditioned APCs exhibit reduced capacity for Th1 polarization through B7-H1. This data indicates that as an effector cytokine, IFN-
can down-regulate active immune responses through induction of B7-H1 on APCs. IFN-
has been shown to stimulate the expression of IDO and arginase on APCs (25, 26). Such APCs could suppress antitumor immune responses. IFN-
was also found to mediate CD4+ T cell loss and impair secondary antitumor immune responses (27). Indeed, the physiological functions of inhibitory B7-family members are to limit and attenuate T cell responses, by which they prevent T cell hyperactivation and avoid tissue and organ damage during immune responses (16, 17, 18). The data suggest that by inducing suppressive molecules on APCs, IFN-
may participate in terminating acute inflammation.
In the absence of exogenous cytokines, APCs are capable of inducing human Th17 cells, basically from memory Th17 cell expansion. This effect is dramatically amplified by IFN-
treatment. This observation may explain why IL-17+ T cells exhibit a memory phenotype and are often found in inflammatory tissues and organs. We demonstrate the mechanisms by which APCs and IFN-
-conditioned APCs induce memory Th17 cell expansion. APCs induce memory Th17 expansion through IL-1 and IL-23, and IFN-
further triggers APCs to produce high levels of IL-1 and IL-23, which in turn induce memory Th17 expansion. This effect is B7-H1 independent. Therefore, IFN-
may play dual roles in regulating the IL-17+ T cell pool as follows: IFN-
targets APCs to initiate and promote Th17 polarization of memory T cells (this study), whereas it targets naive T cells and suppresses Th17 polarization (1, 2, 3, 5, 28).
In summary, we show that IFN-
stimulates B7-H1 expression on APCs and abates the Th1 polarization capacity of APCs through B7-H1, whereas IFN-
can condition APCs to induce Th17 cell expansion from memory T cells through IL-1 and IL-23 in a B7-H1-independent manner. We propose a novel kinetic development and interaction between Th1 and Th17 cells in the course of inflammation as follows: Th1-mediated inflammation is attenuated by IFN-
-induced B7-H1 and subsequently evolves toward Th17-mediated chronic inflammation by IFN-
-induced IL-1 and IL-23. Therefore, our study reveals a novel regulatory role for IFN-
in controlling the evolution of inflammation and challenges the dogma that IFN-
suppresses Th17 and enhances Th1 development.
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was partially supported by National Cancer Institute, National Institutes of Health Grants CA123088 and CA099985 (to W.Z.) and by the Marsha Rivkin Center for Ovarian Cancer Research (to I.K.). ![]()
2 Address correspondence and reprint requests to Dr. Weiping Zou, University of Michigan School of Medicine, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0346. E-mail address: wzou{at}med.umich.edu ![]()
3 Abbreviations used in this paper: MDDC, monocyte-differentiated dendritic cell; siRNA, small interfering RNA. ![]()
Received for publication July 25, 2008. Accepted for publication September 11, 2008.
| References |
|---|
|
|
|---|
mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat. Med. 13: 354-360. [Medline]This article has been cited by other articles:
![]() |
I. Horie, N. Abiru, Y. Nagayama, G. Kuriya, O. Saitoh, T. Ichikawa, Y. Iwakura, and K. Eguchi T Helper Type 17 Immune Response Plays an Indispensable Role for Development of Iodine-Induced Autoimmune Thyroiditis in Nonobese Diabetic-H2h4 Mice Endocrinology, November 1, 2009; 150(11): 5135 - 5142. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Groneck, D. Schrama, M. Fabri, T. L. Stephen, F. Harms, S. Meemboor, H. Hafke, M. Bessler, J. C. Becker, and W. M. Kalka-Moll Oligoclonal CD4+ T Cells Promote Host Memory Immune Responses to Zwitterionic Polysaccharide of Streptococcus pneumoniae Infect. Immun., September 1, 2009; 77(9): 3705 - 3712. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kryczek, M. Banerjee, P. Cheng, L. Vatan, W. Szeliga, S. Wei, E. Huang, E. Finlayson, D. Simeone, T. H. Welling, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments Blood, August 6, 2009; 114(6): 1141 - 1149. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Brand Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease Gut, August 1, 2009; 58(8): 1152 - 1167. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Hinrichs, A. Kaiser, C. M. Paulos, L. Cassard, L. Sanchez-Perez, B. Heemskerk, C. Wrzesinski, Z. A. Borman, P. Muranski, and N. P. Restifo Type 17 CD8+ T cells display enhanced antitumor immunity Blood, July 16, 2009; 114(3): 596 - 599. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |